Device Trial Radar · NCT07943182
Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Abiomed Inc.Public (JNJ)
- Sponsor type
- Industry
- Collaborators
- Johnson & Johnson
- First posted
- Nov 17, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-approval study will evaluate the real-world safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist heart pumps in pediatric patients with cardiogenic shock or severe heart failure requiring temporary mechanical circulatory support. The study will collect data from children and young adults younger than 22 years of age who receive an Impella device as part of their routine clinical care at hospitals participating in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry. The primary objective is to assess survival at the time the Impella device is removed. Information collected during the patient's hospitalization, including clinical outcomes and adverse events, will be used to further evaluate the performance of these commercially approved devices in the pediatric population.
Conditions
- Cardiogenic Shock
- Heart Failure
- Acute Decompensated Heart Failure (ADHF)
- Cardiomyopathy
- Myocarditis
Interventions
Impella CP with SmartAssistDevice
Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.
Impella 5.5 with SmartAssistDevice
Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival rate at Impella Device ExplantTime frame: From date of Impella implant until Impella device explant or date of death from any cause, whichever is first. The duration of time allotted until explant is not pre-specified in the study protocol but is estimated up to 12 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Loma Linda University Children's Hospital
Loma Linda, California
Children's Hospital Los Angeles
Los Angeles, California
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.